Novartis Global CEO Wan Sihan: Based on China's innovat

The China Development Forum 2025 Annual Meeting, hosted by the Development Research Center of the State Council, will be grandly held in Beijing from March 23 to 24, 2025. This forum focuses on the theme of "fully unleashing development momentum and jointly promoting stable global economic growth", attracting hundreds of guests including high-level officials from the Chinese government, global business leaders, international organizations, and renowned scholars from China and abroad to discuss development plans. ​

Novartis CEO Vasant Narasimhan was invited as an important guest to attend and deliver a wonderful speech. He spoke with deep emotion, "Novartis has been rooted in China for many years and has had the privilege of deeply participating in and witnessing the huge leap of China's pharmaceutical innovation ecosystem. Every change is like injecting a strong driving force, releasing vitality and surging momentum. In recent years, China's policy support and regulatory reforms in the field of pharmaceutical innovation have created extremely broad development space for multinational enterprises and enormous development opportunities. Novartis has also benefited greatly from it. We are always committed to introducing globally leading innovative drugs and cutting-edge therapies into China at a faster pace, continuously expanding the accessibility of medicine and health. At the same time, we actively deepen mutual trust with all sectors of society, and work together to help China achieve long-term and sustainable development

At the 2025 Annual Meeting of the China Development Forum, Novartis focused on the key topic of "high-quality development of the big health industry" and shared in depth the practical path of the two core concepts of "innovation and collaboration". Not only that, Novartis also gave a detailed introduction to the attendees about its breakthrough progress in the cutting-edge field of radioligand therapy. As one of the five key technology platforms focused on by Novartis, radioligand therapy has been deeply deployed and actively explored in this field since 2017, gradually establishing a wide range of influence. Nowadays, Novartis is making every effort to introduce this cutting-edge therapy into China, planning to introduce not just a single drug, but an advanced treatment platform technology with the potential to cross multiple cancer types. ​

In addition, Novartis actively submitted policy recommendation reports. The report put forward a series of constructive suggestions, including optimizing and improving the clinical application system of nuclear medicine, scientifically distinguishing between radioactive drugs and radioactive materials, improving the relevant standards for the clinical use of radioactive drugs, as well as improving the regulatory guidelines for the registration of radioactive drugs, and further encouraging the research and development of radioactive drugs. Novartis calls on all parties to work together and promote full industry chain collaboration, committed to establishing a sustainable ecological environment that supports the radiopharmaceutical industry. ​

High quality development has become the core driving force and important pillar of China's current and future economic development, and technological development, especially emerging technologies including artificial intelligence, is a new engine driving high-quality development. Wan Sihan said, "Currently, scientific research is in an unprecedented stage of rapid development. From gene therapy to digital health solutions, we are witnessing a technological revolution that covers all aspects of disease prevention, diagnosis, and treatment. At Novartis, we actively utilize cutting-edge technologies such as artificial intelligence and data science to accelerate the development of breakthrough drugs and strive to provide patients with the innovative drugs they urgently need

Wan Sihan further emphasized: "The health industry has unlimited potential for improving people's livelihoods and driving economic growth. Looking ahead to the future, Novartis will always adhere to the patient-centered concept, continue to strengthen multi-party cooperation, and empower global patients with innovative breakthroughs. We will also continue to uphold the original intention of 'committing to China', continuously introduce innovative cutting-edge technologies and drugs, effectively improve patient health conditions, assist industry development, and continuously contribute Novartis' strength to achieve the grand goal of a healthy China